ECSP21067052A - Formulación sólida del modulador de ensamblaje de la cápside - Google Patents

Formulación sólida del modulador de ensamblaje de la cápside

Info

Publication number
ECSP21067052A
ECSP21067052A ECSENADI202167052A ECDI202167052A ECSP21067052A EC SP21067052 A ECSP21067052 A EC SP21067052A EC SENADI202167052 A ECSENADI202167052 A EC SENADI202167052A EC DI202167052 A ECDI202167052 A EC DI202167052A EC SP21067052 A ECSP21067052 A EC SP21067052A
Authority
EC
Ecuador
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
ECSENADI202167052A
Other languages
English (en)
Inventor
Dominique Verstraete
michael Anne
Abhishek Singh
DYCKE Frederic VAN
Oliver Lenz
Jan Snoeys
Maria Jansens
Claire Balmain
Joris Vandenbossche
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/352,754 external-priority patent/US10973801B2/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of ECSP21067052A publication Critical patent/ECSP21067052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a formas farmacéuticas orales sólidas un inhibidor de ensamblaje de la cápside para el tratamiento de la infección por el virus de la hepatitis B.
ECSENADI202167052A 2019-03-13 2021-09-10 Formulación sólida del modulador de ensamblaje de la cápside ECSP21067052A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP2019056348 2019-03-13
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP19197566 2019-09-16

Publications (1)

Publication Number Publication Date
ECSP21067052A true ECSP21067052A (es) 2021-11-18

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202167052A ECSP21067052A (es) 2019-03-13 2021-09-10 Formulación sólida del modulador de ensamblaje de la cápside

Country Status (16)

Country Link
EP (1) EP3937928A1 (es)
JP (1) JP2022524819A (es)
KR (1) KR20210137484A (es)
CN (1) CN113557016A (es)
AU (1) AU2020235442A1 (es)
BR (1) BR112021017525A2 (es)
CA (1) CA3132095A1 (es)
CR (1) CR20210481A (es)
EC (1) ECSP21067052A (es)
IL (1) IL286209A (es)
JO (1) JOP20210250A1 (es)
MA (1) MA55280A (es)
MX (1) MX2021011030A (es)
PE (1) PE20212107A1 (es)
SG (1) SG11202109710QA (es)
WO (1) WO2020183020A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
EA202092171A1 (ru) * 2018-03-14 2020-12-01 Янссен Сайенсиз Айрлэнд Анлимитед Компани Схема дозирования модулятора сборки капсида

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EA202092171A1 (ru) * 2018-03-14 2020-12-01 Янссен Сайенсиз Айрлэнд Анлимитед Компани Схема дозирования модулятора сборки капсида

Also Published As

Publication number Publication date
MX2021011030A (es) 2021-10-13
JOP20210250A1 (ar) 2023-01-30
CA3132095A1 (en) 2020-09-17
PE20212107A1 (es) 2021-11-04
CN113557016A (zh) 2021-10-26
KR20210137484A (ko) 2021-11-17
SG11202109710QA (en) 2021-10-28
EP3937928A1 (en) 2022-01-19
MA55280A (fr) 2022-01-19
CR20210481A (es) 2021-10-25
JP2022524819A (ja) 2022-05-10
WO2020183020A1 (en) 2020-09-17
AU2020235442A1 (en) 2021-08-12
IL286209A (en) 2021-10-31
BR112021017525A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
CL2021000227A1 (es) Regimen posologico del modulador del ensamblaje de la capside. (divisional de solicitud 2254-2020)
CL2019000415A1 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih.
CO2024006742A2 (es) Compuestos terapéuticos para la infección por el virus del vih
UY35362A (es) Compuestos terapéuticos
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
MX383447B (es) Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
ECSP21067052A (es) Formulación sólida del modulador de ensamblaje de la cápside
CL2020001358A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
EA201890818A1 (ru) Режим комбинированной терапии для лечения hcv
MX2022008062A (es) Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d.
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c
PL409016A1 (pl) N-sulfonowa pochodna polialliloaminy, zastosowanie N-sulfonowej pochodnej polialliloaminy jako leku, zwłaszcza do profilaktyki i leczenia infekcji wirusem grypy typu A (IAV) oraz kompozycja farmaceutyczna zawierająca N-sulfonową pochodną polialliloaminy